Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor

Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively

Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively

Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Novel glucokinase activator (GKA)

Novel mGlu2/3 receptor agonist; Prodrug of LY-404039

Potent antioxidant, being cytoprotective in models of focal and global cerebral ischemia

Selective negative allosteric modulator of mGlu3

Potent 5-HT3 serotonin receptor antagonist

Orally active cell-permeable inhibitor of human

Novel, potent, and systemically bioavailable mGlu2/3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo

Selective cell permeable phosphatidylinositol 3-kinase (PI3K) inhibitor

Novel highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3

Potent and selective inhibitor of PKCβI and PKCβII

Potent GluR5 kainate receptor agonist

Selective GluR5 kainate receptor antagonist

AMPA receptor potentiator

Allosteric modulator of AMPA receptors

Orally active ghrelin agonist, bindjng with high affinity to and being a potent activator of the growth hormone secretagogue receptor 1a (GHS-R1a) receptor

AMPA receptor potentiator

Selective mGlu1 receptor antagonist

Novel potent and selective dual PPARalpha/gamma agonist